AAPL308.16-1.22 (-0.39%) ▼|ABBV245.74+1.94 (+0.80%) ▲|ABT104.64-0.82 (-0.78%) ▼|ACN170.16-0.27 (-0.16%) ▼|ADBE257.84+0.35 (+0.13%) ▲|AMAT539.78-6.84 (-1.25%) ▼|AMD487.12-31.46 (-6.07%) ▼|AMGN403.06+13.04 (+3.34%) ▲|AMT166.76-8.50 (-4.85%) ▼|AMZN271.15-6.27 (-2.26%) ▼|AVGO420.76+2.60 (+0.62%) ▲|AXP347.71+1.00 (+0.29%) ▲|BA239.28+2.12 (+0.89%) ▲|BAC63.45+0.55 (+0.87%) ▲|BKNG207.18+12.91 (+6.65%) ▲|BLK1,128.34-2.79 (-0.25%) ▼|BMY63.71-2.18 (-3.31%) ▼|BNY159.51+2.69 (+1.72%) ▲|BRK-B516.49-0.73 (-0.14%) ▼|C138.16+1.29 (+0.94%) ▲|CAT887.14+10.60 (+1.21%) ▲|CL93.29+0.76 (+0.82%) ▲|CMCSA24.59-0.35 (-1.38%) ▼|COF221.68-0.24 (-0.11%) ▼|COP116.15-1.79 (-1.52%) ▼|COST940.52-7.33 (-0.77%) ▼|CRM192.45+1.46 (+0.76%) ▲|CSCO122.96+1.22 (+1.00%) ▲|CVS99.72-4.70 (-4.50%) ▼|CVX187.33-3.07 (-1.61%) ▼|DE613.30-4.07 (-0.66%) ▼|DHR198.08+3.30 (+1.69%) ▲|DIS101.48+3.30 (+3.36%) ▲|DUK123.19-1.09 (-0.87%) ▼|EMR162.44+3.60 (+2.27%) ▲|FDX311.10-2.24 (-0.71%) ▼|GD382.85-2.91 (-0.75%) ▼|GE380.85+3.57 (+0.95%) ▲|GEV1,030.15+11.62 (+1.14%) ▲|GILD131.29-3.96 (-2.93%) ▼|GM89.11+0.80 (+0.91%) ▲|GOOG360.82-14.53 (-3.87%) ▼|GOOGL362.78-14.87 (-3.94%) ▼|GS1,073.67+20.69 (+1.97%) ▲|HD351.58+3.34 (+0.96%) ▲|HON248.44-0.36 (-0.14%) ▼|IBM237.14+1.99 (+0.85%) ▲|INTC102.23+1.37 (+1.36%) ▲|INTU325.37+1.77 (+0.55%) ▲|ISRG374.72+6.46 (+1.75%) ▲|JNJ258.38+3.45 (+1.35%) ▲|JPM360.55+3.03 (+0.85%) ▲|KO86.76+0.20 (+0.23%) ▲|LIN491.60+6.96 (+1.44%) ▲|LLY1,159.61+43.93 (+3.94%) ▲|LMT580.35-8.99 (-1.52%) ▼|LOW219.14+1.06 (+0.49%) ▲|LRCX312.17-5.57 (-1.75%) ▼|MA571.41+0.31 (+0.05%) ▲|MCD272.64+4.30 (+1.60%) ▲|MDLZ62.53+0.45 (+0.72%) ▲|MDT85.59-0.61 (-0.71%) ▼|META582.87-5.07 (-0.86%) ▼|MMM182.79+1.34 (+0.74%) ▲|MO68.15+0.08 (+0.11%) ▲|MRK128.69+0.69 (+0.54%) ▲|MS219.17+2.13 (+0.98%) ▲|MSFT489.21-3.60 (-0.73%) ▼|MU918.35+25.68 (+2.88%) ▲|NEE85.84-1.36 (-1.56%) ▼|NFLX73.46-0.11 (-0.15%) ▼|NKE42.03+0.50 (+1.21%) ▲|NOW116.90-1.25 (-1.05%) ▼|NVDA221.60+9.66 (+4.56%) ▲|ORCL144.20-1.54 (-1.06%) ▼|PEP138.62-0.48 (-0.35%) ▼|PFE25.55+0.14 (+0.55%) ▲|PG146.69-1.32 (-0.89%) ▼|PLTR159.42-3.24 (-1.99%) ▼|PM189.38+2.47 (+1.32%) ▲|QCOM157.84-4.83 (-2.97%) ▼|RTX221.68+3.75 (+1.72%) ▲|SBUX105.61+0.64 (+0.61%) ▲|SCHW108.27+1.92 (+1.81%) ▲|SO92.78-0.47 (-0.50%) ▼|SPG225.22-0.68 (-0.30%) ▼|T22.88-0.50 (-2.14%) ▼|TMO575.72+10.97 (+1.94%) ▲|TMUS172.75-4.46 (-2.52%) ▼|TSLA321.03-6.32 (-1.93%) ▼|TXN278.38-5.26 (-1.85%) ▼|UBER67.38-4.62 (-6.41%) ▼|UNH415.81+8.26 (+2.03%) ▲|UNP294.69-1.66 (-0.56%) ▼|UPS107.91-1.21 (-1.10%) ▼|USB64.42+0.19 (+0.30%) ▲|V368.86-0.73 (-0.20%) ▼|VZ45.79-1.10 (-2.34%) ▼|WFC89.26+0.87 (+0.98%) ▲|WMT111.67+0.12 (+0.11%) ▲|XOM152.18-1.78 (-1.16%) ▼|AAPL308.16-1.22 (-0.39%) ▼|ABBV245.74+1.94 (+0.80%) ▲|ABT104.64-0.82 (-0.78%) ▼|ACN170.16-0.27 (-0.16%) ▼|ADBE257.84+0.35 (+0.13%) ▲|AMAT539.78-6.84 (-1.25%) ▼|AMD487.12-31.46 (-6.07%) ▼|AMGN403.06+13.04 (+3.34%) ▲|AMT166.76-8.50 (-4.85%) ▼|AMZN271.15-6.27 (-2.26%) ▼|AVGO420.76+2.60 (+0.62%) ▲|AXP347.71+1.00 (+0.29%) ▲|BA239.28+2.12 (+0.89%) ▲|BAC63.45+0.55 (+0.87%) ▲|BKNG207.18+12.91 (+6.65%) ▲|BLK1,128.34-2.79 (-0.25%) ▼|BMY63.71-2.18 (-3.31%) ▼|BNY159.51+2.69 (+1.72%) ▲|BRK-B516.49-0.73 (-0.14%) ▼|C138.16+1.29 (+0.94%) ▲|CAT887.14+10.60 (+1.21%) ▲|CL93.29+0.76 (+0.82%) ▲|CMCSA24.59-0.35 (-1.38%) ▼|COF221.68-0.24 (-0.11%) ▼|COP116.15-1.79 (-1.52%) ▼|COST940.52-7.33 (-0.77%) ▼|CRM192.45+1.46 (+0.76%) ▲|CSCO122.96+1.22 (+1.00%) ▲|CVS99.72-4.70 (-4.50%) ▼|CVX187.33-3.07 (-1.61%) ▼|DE613.30-4.07 (-0.66%) ▼|DHR198.08+3.30 (+1.69%) ▲|DIS101.48+3.30 (+3.36%) ▲|DUK123.19-1.09 (-0.87%) ▼|EMR162.44+3.60 (+2.27%) ▲|FDX311.10-2.24 (-0.71%) ▼|GD382.85-2.91 (-0.75%) ▼|GE380.85+3.57 (+0.95%) ▲|GEV1,030.15+11.62 (+1.14%) ▲|GILD131.29-3.96 (-2.93%) ▼|GM89.11+0.80 (+0.91%) ▲|GOOG360.82-14.53 (-3.87%) ▼|GOOGL362.78-14.87 (-3.94%) ▼|GS1,073.67+20.69 (+1.97%) ▲|HD351.58+3.34 (+0.96%) ▲|HON248.44-0.36 (-0.14%) ▼|IBM237.14+1.99 (+0.85%) ▲|INTC102.23+1.37 (+1.36%) ▲|INTU325.37+1.77 (+0.55%) ▲|ISRG374.72+6.46 (+1.75%) ▲|JNJ258.38+3.45 (+1.35%) ▲|JPM360.55+3.03 (+0.85%) ▲|KO86.76+0.20 (+0.23%) ▲|LIN491.60+6.96 (+1.44%) ▲|LLY1,159.61+43.93 (+3.94%) ▲|LMT580.35-8.99 (-1.52%) ▼|LOW219.14+1.06 (+0.49%) ▲|LRCX312.17-5.57 (-1.75%) ▼|MA571.41+0.31 (+0.05%) ▲|MCD272.64+4.30 (+1.60%) ▲|MDLZ62.53+0.45 (+0.72%) ▲|MDT85.59-0.61 (-0.71%) ▼|META582.87-5.07 (-0.86%) ▼|MMM182.79+1.34 (+0.74%) ▲|MO68.15+0.08 (+0.11%) ▲|MRK128.69+0.69 (+0.54%) ▲|MS219.17+2.13 (+0.98%) ▲|MSFT489.21-3.60 (-0.73%) ▼|MU918.35+25.68 (+2.88%) ▲|NEE85.84-1.36 (-1.56%) ▼|NFLX73.46-0.11 (-0.15%) ▼|NKE42.03+0.50 (+1.21%) ▲|NOW116.90-1.25 (-1.05%) ▼|NVDA221.60+9.66 (+4.56%) ▲|ORCL144.20-1.54 (-1.06%) ▼|PEP138.62-0.48 (-0.35%) ▼|PFE25.55+0.14 (+0.55%) ▲|PG146.69-1.32 (-0.89%) ▼|PLTR159.42-3.24 (-1.99%) ▼|PM189.38+2.47 (+1.32%) ▲|QCOM157.84-4.83 (-2.97%) ▼|RTX221.68+3.75 (+1.72%) ▲|SBUX105.61+0.64 (+0.61%) ▲|SCHW108.27+1.92 (+1.81%) ▲|SO92.78-0.47 (-0.50%) ▼|SPG225.22-0.68 (-0.30%) ▼|T22.88-0.50 (-2.14%) ▼|TMO575.72+10.97 (+1.94%) ▲|TMUS172.75-4.46 (-2.52%) ▼|TSLA321.03-6.32 (-1.93%) ▼|TXN278.38-5.26 (-1.85%) ▼|UBER67.38-4.62 (-6.41%) ▼|UNH415.81+8.26 (+2.03%) ▲|UNP294.69-1.66 (-0.56%) ▼|UPS107.91-1.21 (-1.10%) ▼|USB64.42+0.19 (+0.30%) ▲|V368.86-0.73 (-0.20%) ▼|VZ45.79-1.10 (-2.34%) ▼|WFC89.26+0.87 (+0.98%) ▲|WMT111.67+0.12 (+0.11%) ▲|XOM152.18-1.78 (-1.16%) ▼|
29 C
New York
Wednesday, August 5, 2026

Tag: Yale School of Medicine

newssourceFORcompanyinformationcontent1releasesmarket

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a...

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsYale School of Medicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers